SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of...
Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC )
Also on site :
- Derek Hough's Mom Can't Get Over What Hayley Erbert Wore on the Hough Family's Disney Trip
- Popular Breyers Ice Cream Flavor Inspires 'Ice-Cold' Innovation
- This ‘DWTS’ Hunk Says He Would Strip Down to Host Chippendales (Exclusive)